LOXL2 and exocrine pancreatic carcinoma: Another LOXL inhibitor a transgenic mouse model of breast cancer has shown an anti-LOXL2 monoclonal mouse antibody, AB0023, which has shown efficacy in lowering intratumoral collagen-like density in a rat pancreas carcinoma model, Subsequently, a humanistic form of this antibody, simtuzumab, has been developed to inhibit allosteric activity by binding to the fourth SRCR domain of LOXL2, a non-competitive extracellular LOXL2 inhibitor.